Shionogi Surges 63% Revenue, Eyes U.S. Expansion and 2027 Growth Target
Shionogi’s Q1 2026 beats expectations with 63.7% revenue growth, strong EPS lift, and aggressive U.S. expansion & acquisition plans for future growth.
3 minutes to read
SHIONOGI & CO LTD
Shionogi & Virchow Labs Partnership Highlights Pharma Supply‑Chain Risks & Opportunities
Shionogi & Co. partners with Virchow Laboratories to secure high‑purity components for sulfamethoxazole, highlighting strategic supply‑chain alliances and the risks they pose to the pharma industry.
3 minutes to read